Just like bad medicine...Trump tariff pricks again; India not seen badly hit by US’ latest salvo

US President Trump’s 100% tariff on pharmaceutical products targets only branded and patented drugs, leaving India’s generic exports largely unaffected, experts say. The tariff, effective October 1, spooked pharma stocks but poses minimal immediate risk. India exported $9.8 billion in pharma to the US in FY25. Tariffs on furniture and trucks may benefit India, while bilateral trade talks continue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BroP82Q
via IFTTT